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Perspectives on the COVID-19 pandemic
impact on cardio-oncology: results from the
COVID-19 International Collaborative
Network survey
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Eric H. Yang7, Sebastian Szmit8, Nausheen Akhter9, Monika Leja10, Carolina Maria Pinto Domingues Carvalho Silva11,
Jayant Raikhelkar12, Sherry-Ann Brown13, Susan Dent14, Rupal O’Quinn15, Franck Thuny16, Rohit Moudgil17,
Luis E. Raez18, Tochukwu Okwuosa19, Andres Daniele20, Brenton Bauer21, Lavanya Kondapalli22, Roohi Ismail-Khan23,
Jorge Lax24, Anne Blaes25, Zeina Nahleh1, Leah Elson1, Lauren A. Baldassarre26, Vlad Zaha27, Vijay Rao28,
Daniel Sierra Lara29, Kerry Skurka28 and on behalf of the Cardio-Oncology International Collaborative Network

Abstract
Background: Re-allocation of resources during the COVID-19 pandemic has resulted in delays in care delivery to
patients with cardiovascular disease and cancer. The ability of health care providers to provide optimal care in this
setting has not been formally evaluated.
Objectives: To assess the impact of COVID-19 resource re-allocation on scheduling, testing, elective procedures,
telemedicine access, use of new COVID-19 therapies, and providers’ opinions on healthcare policies among
oncology and cardiology practitioners.
Methods: An electronic survey was conducted by a cardio-oncology collaborative network through regional and
state chapters of the American College of Cardiology, American Society of Clinical Oncology, and the International
Cardio-Oncology Society. Descriptive statistics were reported by frequency and proportion for analyses, and
stratified categorically by geographic region and specialty.
Results: One thousand four hundred fifteen providers (43 countries) participated: 986 cardiologists, 306 oncologists,
and 118 trainees/internal medicine. 63% (195/306) of oncologists vs 92% (896/976) of cardiologists reported
cancellations of treatments/elective procedures (p = 0.01). 46% (442/970) of cardiologists and 25% (76/303) of
oncologists modified the scope of their practice (p = < 0.001). Academic physicians (74.5%) felt better supplied with
personal protective equipment (PPE) vs non-academic (74.5% vs 67.2%; p = 0.018). Telemedicine was less common
in Europe 81% (74/91), and Latin America 64% (101/158), than the United States, 88% (950/1097) (p = < 0.001). 95%
of all groups supported more active leadership from medical professional societies.
(Continued on next page)
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Conclusions: These results support initiatives to promote expanded coverage for telemedicine, increased access to
PPE, better testing availability and involvement of medical professional societies to help with preparedness for
future health care crisis.
Keywords: COVID-19, Health policy, Global Health, Cardio oncology

Introduction
The coronavirus disease 2019 (COVID-19) pandemic
has resulted in substantial morbidity and mortality
across the world, with over 30 million cases, and 1
millon deaths worldwide, as of late September 2020 [1].
Almost every country has now been significantly impacted. With this, there has been a massive shift of medical resources focusing on the testing and treatment of
COVID-19 patients, resulting in delays of other, nonCOVID-19-related medical care, including that required
for cardiovascular diseases (CVD) and cancer, the two
leading causes of death in the western world [2].
Importantly, patients with pre-existing CVD and cancer are particularly vulnerable to the severe acute respiratory syndrome corona virus 2 (SARS CoV-2), the
agent responsible for the COVID-19 pandemic, with increased morbidity and mortality [3–7]. In addition to the
direct infliction by COVID-19, these patient population
are severely affected in an indirect manner by the change
in health care resource allocations. These include rescheduling or postponing of cardiac testing, procedures,
advanced imaging, and cancer treatments, and the effects of these are emerging [8–11]. Of those directly caring for patients with COVID-19, efforts were at times
thwarted by critical supply shortages leading to inadequate testing and PPE, further complicated by, at times,
tepid institutional support [12–17]. The impact of the
COVID 19 pandemic on subgroups of health care providers has recently been reported [18, 19], but cardiologists’ and oncologists’ opinions and needs throughout
this global health crisis have not been formally evaluated.
Such data are important to foster a better understanding
of the impact and future preparedness of healthcare crises. The current survery was conducted among cardiologists and oncologists based on a Cardio-Oncology
collaborative network with members of regional and
state Chapters of the American College of Cardiology
(ACC), American Society of Clinical Oncology (ASCO)
and the International Cardio Oncology Society (ICOS).
The summary results and recommendations from this
survery are reported herein.
Methods
We conducted a survey between March 24th and April
17th 2020 to measure the impact of the pandemic on
provider practices and the availability of resources

worldwide. A link to the electronic survey (Apendix) was
sent via e mail by local professional societies on behalf
of the ACC/ASCO/ICOS State Chapter collaborative
network, supported by members of 19 states within the
United States (US) and 10 countries. E-mail reminders
were sent to potential responders on the second and
third week by the participating sites. The Survey had 20
questions, 7 collected demographics and 13 questions
collected information about resources, treatments, institutional support and opinions on the COVID 19 pandemic response. The survey targeted primarily adult
cardiologists and oncologists but also included a small
number of internal medicine physicians. We compared
the responses of cardiologists versus oncologists, academic versus non academic practices, and the respondents by geographic area. Participants received no
incentives or compensation. No personal, health, or protected information was obtained with this survey.
All responses were included for analysis, except for geographic comparisons where only North America, Europe
and Latin America were included given the small numbers
from other locations. The Florida Chapter of the ACC collected the electronic survey data. Data was directly and securely exported to Microsoft Excel (2010). Descriptive
statistics were reported via frequency and proportion for
analyses, and stratified categorically by geographic region
and specialty. Chi square analysis was performed to establish statistical differences between categorical variables,
and two-tailed p-values were reported. Bonferroni correction was used for comparisons between three groups.
There were no continuous variables in this survey. Statistical significance was interpreted based on an α-value <
0.05. All data analyses were performed using SPSS, version
26 (IBM, Aramonk, NY).

Results
Demographics

There were 1415 respondents to the survey from 43
countries: By global region, 1124 were from North
America (US and Canada), 158 from Latin America, 93
from Europe, 15 from Asia, 6 from Australia and 3 from
Africa. The geographic distribution of respondents is
depicted in the Fig. 1.
Among the respondents, there were 986 cardiologists,
306 oncologists, and 118 classified as others including
trainees and internal medicine providers (Fig. 2). Gender
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Fig. 1 Distribution of Respondents: World map displaying color-coded regions wherein survey respondents to the international survey are
currently practicing. Countries with > 5 respondents are listed, with their respective respondent numbers

representation varied by specialty. Sixty-five percent
(642/ 986) of the cardiology respondents were males but
67% (207/306) of the oncology respondents were females
(p = < 0.001). A hospital-based practice was reported by
40% of both cardiologists and oncologists. Thirty percent
(298/980) of cardiologists and 41% (127/306) of oncologists were working in academic settings.

Impact of pandemic in practice patterns including
scheduling, testing, procedures

Ninety-two percent (1292/1402) of survey participants reported rescheduling patients as a result of
the pandemic, a response that was remarkably similar across all surveyed groups and locations. Ninetytwo percent (896/976) of cardiologists versus 63%
(195/306) of oncologists reported cancellations of
elective procedures/day-unit cancer outpatient treatment due to the pandemic (p = 0.01). Similarly, decreased use of diagnostic cardiovascular (CV)
imaging was reported by 81% (791/976) of cardiologists but only 39% (120/305) of oncologists (p = <
0.001). These diagnostic modalities were cancelled in
71% (911/1281) of physician practices in the US,
53% (84/158) in Latin America and 69% (64/93) in
Europe at the time of the survey (Fig. 3).

Oncology treatment modification to balance increased
risk of exposure was reported by 72% (221/305) of
oncologists.
Deployment of physicians

Forty-six percent (442/970) of cardiologists but only 25%
(76/303) of oncologists were asked to modify the scope
of their specialized practice and redeploy from specialty
care to help with acute patient care during the initial
phase of the COVID-19 health care crisis (p = < 0.001)
(Table 1). The change of scope of practice was higher in
non US locations: 96/156 (62%) of Latin America and
61/93 (66%) of European providers as opposed to 368/
1081 (34%) of US providers reported a temporary change
in their scope of practice (p = < 0.001) (Table 3).
Available physician resources during the pandemic
PPE

Concern about PPE was reported by both cardiologists
and oncologists. Overall, physicians reported that their
institutions provided proper protection to all healthcare
workers for 66% (644/974) of the respondents in March,
and to 78.5% (314/400) in April. Physicians practicing in
academic institutions felt better supplied with PPE. For
instance, 74.4% (360/483) of academic vs 67.4% (611/
909) of non-academic private practice and hospital based
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Fig. 2 Reported Medical Specialties: Distribution of respondents, per self-identified medical specialty: includes cardiology, oncology, internal
medicine, and other. Most respondents practiced cardiology, followed by oncology

Fig. 3 How Has COVID Affected Your Practice? Impact of COVID-19 in practice patterns, stratified by geographic region

839 (86.1%)
690 (71.5%)
885 (91.5%)
730 (75.1%)
130 (15.1%)
289 (32.7%)
826 (85.7%)
926 (95.2%)

“Have you had in service instruction/guidelines from leadership at your institution about policies to
protect your patients, your team, your colleagues and yourself?”

“Do you feel you have adequate support from your institution’s leadership to carry on with your
duties?”

“Do you discuss with all your patients the importance of strict adherence to COVID-19 community
behavior as part of your office/clinic encounters?”

“Do you have access to COVID-19 testing at your institution or local lab?”

“Has your institution used Tocilizumab or other anti-inflammatory agents for COVID-19 related
myocarditis?”

Has your institution used empiric treatment with Remdesivir or other anti-viral treatments for
the sickest patients?

“In your opinion, should there be a government mandated nationwide quarantine/lock-down
to slow down the propagation/transmission of COVID-19?”

“Should medical professional organizations take a more active role, and have more influence in
official health care policy decisions during this major crisis?”

47 (4.8%

138 (14.3%)

595 (67.3%)

733 (84.9%)

242 (24.9%)

82 (8.5%)

275 (28.5%)

136 (13.9%)

529 (54.5%)

151 (15.0%)

818 (85.0%)
442 (45.5%)

“Do you use telemedicine to reduce in-person encounters and health care providers’ exposure?”

“Have you been asked to reduce your specialized practice to help/contribute to other areas where
urgent help is needed?”

385 (43.6%)

498 (56.4%)

“Have timely surgery/chemo/immunotherapy treatments for your patients been delayed since the
COVID-19 pandemic started?”

285 (29.4%)

684 (70.6%)

289 (95.7%)

259 (86.6%)

69 (26.1%)

42 (16.7%)

205 (67.4%)

285 (95%)

232 (76.1%)

272 (89.2%)

76 (25.2%)

269 (89.4%)

152 (50%)

210 (69.3%)

Oncologists
Yes (n (%))

Yes (n (%))

No (n (%))

Cardiologists

“Does your institution provide proper protection for all health care workers to the level they are
exposed?”

Survey Question

Table 1 Responses: cardiologists vs oncologists; p-values determined via chi-squared analysis

13 (4.3%)

40 (13.4%)

195 (73.9%)

210 (83.3%)

99 (32.6%)

15 (5%)

73 (23.9%)

33 (10.8%)

226 (74.8%)

32 (10.6%)

152 (50%)

93 (30.7%)

No (n (%))

P-value

P = 0.931

P = 0.909

P = 0.035

P = 0.059

P = 0.017

P = 0.141

P = 0.030

P = 0.168

P < 0.001

P = 0.085

P < 0.001

P = 0.598

Statistical
significance < 0.05
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doctors felt their institutions provided proper PPE (p =
0.018) (Table 2). Overall use of PPE was 70.3% (759/
1079) in the US vs. 62.4% (58/93) in Europe and 66.2%
(104/157) in Latin America (p = 0.168).
Testing

At the time of the survey, 75% (730/972) of cardiologists
and 67% (205/305) of oncologists reported having direct
access to COVID-19 testing at their facilities or local
labs (p = 0.017). (Table 1). The availability of COVID-19
testing also had significant geographic variation: 75%
(812/1082) in the US, 67% (62/93) in Europe, and 53.5%
(84/157) in Latin America (p = < 0.001) (Fig. 4). Direct
access to COVID-19 testing was available to 84.1% (407/
484) of doctors working in an academic setting but only
66.7% (607/910) of non-academic affiliated doctors, including those in private practice and hospital-employed
(p = < 0.001) (Table 2).
Telemedicine

More than 85% of both cardiologists and oncologists
adopted telemedicine during the pandemic, and the use
of telemedicine was reported by 82% (798/973) of respondents in March and by 91.5% (366/400) in April.
Telemedicine was more commonly used amongst doctors in academic settings 90.3% (438/484) vs non- academic affiliated doctors 80.2%, (727/907) (p = < 0.001)
(Table 2). The use of telemedicine was less common in
Europe and Latin America, 81% (74/91) and (64%) (101/
158), respectively, compared to the US where it was 88%
(950/1097) (P = 0.021 for Europe vs. US; P < 0.001 for
Latin American vs. US) (Table 3).
Use of new medications

Only 33% (289/885) of cardiologists and 26% (69/268) of
oncologists reported the use of remdesivir or other antiviral treatments for COVID-19 at their institutions (p =
0.035); the use of remdesivir or other antiviral drugs was
27.7% (240/865) in March and 34.4% (129/374) in April.
Remdesivir was used by 38% (166/431) in academic vs.
26% (215/826) of private practice and hospital based
non-academic affiliated settings (p = < 0.001). Overall, reported remdesivir use was 33.8% (323/957) in the US,
21% (18/87) in Europe, and 15% (24/156) in Latin America (p = < 0.001) (Fig. 4, Table 3).
Only 15% of both cardiologists and oncologists reported use tocilizumab or other antiinflamatory agents
for COVID related myocarditis. The use of tocilizumab
changed from 11.9% (100/840) in March to 21.3% (78/
366) in April. Tocilizumab was used 22.5% (93/413) in
academic vs. only 11.4% (93/817) of non-academic affiliated practices (p = < 0.001). Its use was more common in
the US at 16.8% (156/927) than in Europe at 11.6% (10/
86), or Latin America at 9% (14/155) (p = < 0.001).

Page 6 of 13

Institutional resources and advocacy

Ninety-three percent (451/485) of doctors in academic
settings versus 83.9% (765/916) of non-academic affiliated
doctors reported to have had in service instruction/guidelines from leadership at their institutions about policies to
protect patients, healthcare team and colleagues at the
time of this survey (p = < 0.001). Eighty percent (391/476)
of doctors in academic settings compared to 67.5% (609/
914) of non-academic affiliated doctors felt they had support from their institutional leadership to carry on with
their duties (p = < 0.001). There was strong support for
stay in place/lock down policies: 85.7% (826/966) of cardiologists and 86.6% (259/300) of oncologists reported support for national lockdowns/stay in place policies. While
support for mandatory lockdown was 84.4% (910/1077)
among US cardiologists and oncologists, it was 91.6%
(142/155) in Latin America and 92.3% (84/91) in Europe
(p = 0.152). The overwhelming majority, 95% of all surveyed groups, felt that professional societies should play a
larger role in health care policy during the pandemic crisis. In these two health care policy areas there was almost
unanimous agreement by physicians in academic medicine
or private practice as well as cardiologists and oncologists
from all geographic areas (Tables 1, 2 and 3).

Discussion
The COVID-19 pandemic has been the largest global healthcare crisis of the century and continues to cause a large
number of deaths despite the containment efforts [1]. The
absence of large-scale testing capabilities with consequent inability to implement successful containment strategy [20],
coupled with lack of effective treatment and nonexistent
immunization [21], has generated an enormous strain and
disruption throughout the world. The emotional and physical toll on healthcare workers, particularly in those areas
hardest hit cannot be overstated [22, 23].
We conducted an international survey during the early
stage of the pandemic to assess its impact on cardiologists and oncologists in different geographic locations
and its effect on scheduling, testing, elective procedures
and delay of treatments, as well as the available resources in the work place including PPE, COVID-19
testing, access to telemedicine, and the use of experimental therapies. We also ascertained the degree of
existing physician support resources including COVID19 related institutional guidelines, and physicians’ opinions about endorsement of national stay in place/lockdown policies and their support for active participation
of professional societies in health care policy making
during a healthcare crisis.
Geographical impact

We explored regional differences in the impact of this
pandemic. There was lower use of telemedicine, less

421 (88.1%)
467 (96.5%)

“In your opinion, should there be a government mandated nationwide quarantine/lock-down
to slow down the propagation/transmission of COVID-19?”

“Should medical professional organizations take a more active role, and have more influence
in official health care policy decisions during this major crisis?”

436 (90.5%)

“Do you discuss with all your patients the importance of strict adherence to COVID-19
community behavior as part of your office/clinic encounters?”

166 (38.6%)

391 (80.3%)

“Do you feel you have adequate support from your institution’s leadership to carry on
with your duties?”

Has your institution used empiric treatment with Remdesivir or other anti-viral
treatments for the sickest patients?

451 (92.6%)

“Have you had in service instruction/guidelines from leadership at your institution about
policies to protect your patients, your team, your colleagues and yourself?”

407 (84.1%)

196 (40.4%)

“Have you been asked to reduce your specialized practice to help/contribute to other
areas where urgent help is needed?”

93 (22.5%)

438 (90.3%)

“Do you use telemedicine to reduce in-person encounters and health care providers’
exposure?”

“Has your institution used Tocilizumab or other anti-inflammatory agents for COVID-19
related myocarditis?”

216 (47.5%)

“Have timely surgery/chemo/immunotherapy treatments for your patients been delayed
since the COVID-19 pandemic started?”

“Do you have access to COVID-19 testing at your institution or local lab?”

360 (74.4%)

17 (3.5%)

57 (11.9%)

264 (61.4%)

320 (77.5%)

77 (15.9%)

46 (9.5%)

96 (19.7%)

36 (7.4%)

289 (59.6%)

47 (9.7%)

239 (52.5%)

124 (25.6%)

861 (94.6%)

766 (84.5%)

215 (26.1%)

93 (11.5%)

607 (66.7%)

837 (92.7%)

609 (67.5%)

765 (83.9%)

356 (39.3%)

727 (80.2%)

479 (56.8%)

611 (67.4%)

Non-Academic
Yes (n (%))

Yes (n (%))

No (n (%))

Academic

“Does your institution provide proper protection for all health care workers to the level
they are exposed?”

Survey Question

Table 2 Academic versus non academic setting; p-values determined by chi-squared analysis

49 (5.4%)

140 (15.5%)

609 (73.9%)

714 (88.5%)

303 (33.3%)

66 (7.3%)

293 (32.5%)

148 (16.2%)

551 (60.7%)

180 (19.8%)

364 (43.2%)

296 (32.7%)

No (n (%))

P-value

0.209

0.186

< 0.001

< 0.001

< 0.001

0.199

< 0.001

< 0.001

0.325

< 0.001

0.157

0.018

Statistical
significance < 0.05
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Fig. 4 PPE, Testing, and New Treatment Availability. Distribution of practices patterns and treatment types utilized in three geographic regions
including, the US, Latin America, and Europe. There use a low use rate for Remdesivir or Tocilizumab, across all three regions; the majority of
respondents report availability of PPE and COVID testing, on-site, across all three regions

COVID-19 testing, and less use of novel treatments like
remdesivir and tocilizumab among Latin America physicians compared US physicians, potentially a reflection of
regional economic differences (Table 3). However, other
observed differences like less cancer treatment cancelation rates may be secondary to the timing of the pandemic with a later presentation in Latin America.
Argentina, a country with strict stay in place/lockdown
policies had lower early infection rates than neighboring
country Brazil, with no lockdown order, and a rapid
growth of COVID-19 cases becoming a world hotspot
for the pandemic [1].
More physicians redeployment for COVID-19 care
and reduction of specialized care was reported in Europe
and Latin America compared to the US, possibly related
to different structure of healthcare systems. Interestingly,
respondents from Latin America and Europe reported
having less institutional leadership support than their US
counterparts.
In the UK, cardiologists were redeployed to “COVID19 wards” and also to provide cardiology support at
some of the new purpose-fitted National Health Service
(NHS) Nightingale field hospitals (https://www.england.
nhs.uk/coronavirus/wp-content/uploads/sites/52/2020/
03/specialty-guide-cardiolgy-coronavirus-v1-20-march.

pdf). Poland established policies for physicians’ redeployment to other geographic locations. Telemedicine and
reimbursement were implemented by the Polish National Health Fund, and recommendation statements for
cancer treatment during the pandemic were issued by
the Polish Society of Clinical Oncology [24].
Impact on patient care

The impact of postponed care and its long term consequences are still unknown. Since community spread
of SARS-CoV-2 was reported in the US, there were
fewer admissions for CVD. A recent retrospective
study from 15 US centers reported a 43% reduction
in hospitalization rates for acute CV conditions including heart failure, acute coronary syndrome (ACS)
and stroke [25, 26]. Likewise, late presentation of
ACS and a variety of COVID-19 related “STEMI like”
presentations emerged and presented unique challenges in management of these patients [27]. Similarly, delays in cancer treatment can result in
devastating consequences. Treatment decisions regarding chemotherapy, immunotherapy, surgery and radiation, were all impacted by the shift of resources
during the peak of the COVID-19 pandemic [28].
Unique strategies to try to mitigate risk without

323 (33.8%)
910 (84.4%)
1035 (95.5%)

Has your institution used empiric treatment with Remdesivir or other anti-viral
treatments for the sickest patients?

“In your opinion, should there be a government mandated nationwide
quarantine/lock-down to slow down the propagation/transmission of COVID-19?”

“Should medical professional organizations take a more active role, and have
more influence in official health care policy decisions during this major crisis?”

270 (25%)

978 (91.1%)

“Do you discuss with all your patients the importance of strict adherence to
COVID-19 community behavior as part of your office/clinic encounters?”
812 (75%)

800 (74.1%)

“Do you feel you have adequate support from your institution’s leadership to
carry on with your duties?”

156 (16.9%)

943 (86.7%)

“Have you had in service instruction/guidelines from leadership at your institution
about policies to protect your patients, your team, your colleagues and yourself?”

“Do you have access to COVID-19 testing at your institution or local lab?”

368 (34%)

“Have you been asked to reduce your specialized practice to help/contribute to
other areas where urgent help is needed?”

“Has your institution used Tocilizumab or other anti-inflammatory agents for
COVID-19 related myocarditis?”

95 (8.9%)

950 (88%)

“Do you use telemedicine to reduce in-person encounters and health care
providers’ exposure?”

49 (4.5%)

168 (15.6%)

632 (66.2%)

768 (83.1%)

279 (25.9%)

145 (13.3%)

713 (66%)

129 (12%)

429 (432%)

565 (56.8%)

“Have timely surgery/chemo/immunotherapy treatments for your patients been
delayed since the COVID-19 pandemic started?”

320 (29.7%)

759 (70.3%)

88 (95.7%)

84 (92.3%)

18 (20.7%)

10 (11.6%)

62 (66.7%)

87 (94.6%)

56 (60.2%)

83 (89.2%)

61 (65.6%)

74 (81.3%)

44 (50%)

58 (62.4%)

Europe
Yes (n (%))

Yes (n (%))

No (n (%))

United States

“Does your institution provide proper protection for all health care workers to the
level they are exposed?”

Survey Question

Table 3 Responses by geographic area; p-values determined via chi-squared analysis with multiple group comparison

4 (4.3%)

7 (7.7%)

69 (79.3%)

76 (88.4%)

31 (33.3%)

5 (5.4%)

37 (39.8%)

10 (10.8%)

32 (34.4%)

17 (18.7%)

44 (50%)

35 (37.6%)

No (n (%))

Latin America

147 (93.6%)

142 (91.6%)

24 (15.4%)

14 (9%)

84 (53.5%)

152 (96.2%)

96 (61.9%)

132 (84.1%)

96 (61.5%)

101 (63.9%)

87 (56.1%)

104 (66.2%)

Yes (n (%))

10 (6.4%)

13 (8.4%)

132 (84.6%)

141 (91%)

73 (46.5%)

6 (3.8%)

59 (38.1%)

25 (15.9%)

60 (38.5%)

57 (36.1%)

68 (43.9%)

53 (33.8%)

No (n (%))

P-value

0.765

0.152

< 0.001

< 0.001

< 0.001

0.035

0.001

0.609

< 0.001

< 0.001

0.009

0.168

Statistical
significance < 0.05
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compromising outcomes were implemented [29]. In
this survey, the reported cancellation of diagnostic
and therapeutic procedures, greater among CV patients than cancer patients, points toward a potential
future burden to the healthcare system for nonCOVID patients due to delayed or deferred care. The
discrepancy in canceled testing and procedures between cardiology and cancer patients likely reflects
the more time sensitive nature of cancer treatment.
In general cancer therapy in the US, Canada and the
UK slowed down but continued even in the worst
weeks of the COVID-19 pandemic [30, 31].
Similarly, cardiologists were asked to modify the
scope of their specialized practice to help with acute
patient care during the initial phase of the pandemic
more often than oncologists. This may be explained
by the acuity of COVID-19 requiring cardiology expertise in acute care management. In addition, the
pandemic crisis transiently reduced cardiology
utilization of specialty procedures and surgeries. This
trend may have already decreased in the US, Canada
and others with the re-introduction of elective non
COVID-19 related CV care [32].
Available resources to physicians: PPE, telemedicine,
novel therapeutics

The lack of PPE was a significant concern for cardiologists and oncologists with only 74.5% of doctors in academic setting and 67% of private practice/hospital-based
doctors feeling they had adequate protection. Similarly,
in a recent survey amongst cardiovascular fellows in
training (FITs) in the US, only 51% reported wearing
N95 masks for all COVID-19 patients, and 41% felt uncomfortable with the PPE recommendations at their institutions [33]. The implications of these findings are
significant beyond the effect on doctors themselves,
since this perceived lack of safety [15, 16] may impact
the doctors’ ability to balance the risk of contagion versus the risk of delayed care.
Telemedicine was infrequently used in most clinical
settings prior to the current pandemic [34]. However,
the use of telemedicine with existing and new platforms were rapidly adopted during the COVID-19
pandemic as a means of reducing risk of infection
[35]. Telemedicine was used more frequently among
April than March respondents, and it was more commonly used in academic settings. Although telemedicine was widely utilized in the US, Canada and UK,
many countries currently lack a regulatory framework
to integrate and reimburse telemedicine services [36].
Telemedicine may improve access to specialty care in
small communities and rural areas and may play a
critical role in the ability to monitor short and longterm CV complications of cancer treatment. However,

Page 10 of 13

the use of this technology may also exacerbate health
care disparities. In a recent study with 2940 patients,
those with poor socioeconomic status, older age, and
non-English speaking had less access to care via telemedicine, particularly video telemedicine [37].
With regard to COVID-19 novel and investigational
treatment, we assessed the utilization rate of two of the
most promising although yet unproven treatments at the
time of the survey. Remdesivir, an inhibitor of the viral
RNA dependent RNA polymerase with activity against
SARS-COV and Middle East Respiratory syndrome
(MERS-COV), has emerged as a potentially useful treatment for patients with advanced COVID-19 [38–40].
Tocilizumab can effectively block the IL-6 signal transduction pathway and could conceptually become an effective drug for patients with severe COVID-19 since
significant morbidity and mortality in the late phase of
disease is attributed to severe cytokine release storm
(CRS) [41, 42]). This drug is also familiar to cardiooncologists since it is utilized for treatment of CAR-T
cell therapy related CRS [41, 42]. The low utilization rate
of both remdesivir and tocilizumab reflects the struggle
to manage this very sick population given the lack of
established and available treatments. Recent promising
new data on the use of remdesivir on patients with severe COVID-19 infection [43, 44], may increase its use
and availability. This survey did not inquire if these
drugs were used off label or as part of a clinical trial.
Physicians input on Health care policy

One of the main goals of our survey was to garner
the opinion of cardiologists and oncologists about the
role of government and professional societies during a
major health care crisis, a topic that is poorly represented in the medical literature. There was very
strong support amongst cardiologists and oncologists
for having national health policies in place (e.g. shelter in place) and a need for a clear and coordinated
national response to the pandemic. Worldwide, different responses by various governments and health care
systems resulted in different outcomes, likely multifactorial given different demographics, cultural habits,
and resources of each country [45, 46]. For instance,
late responses and failure by governments to act early
with containment efforts on the pandemic were associated with widespread and subsequent catastrophic
consequences [47]. The presence of a coordinated,
unified, early response during future crisis may allow
both medical leadership and frontline healthcare
workers to perform their duties with less uncertainty
and better structured support. Indeed, there was an
almost unanimous agreement (95%) among all respondents from all groups in all locations about the
imperative need of a very strong participation of the
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respective professional societies in decision making in
public health, particularly during a global health crisis. The active involvement and input by professional
medical societies in health care policies may be the
instrument that facilitates data driven policies and
subsequent better outcomes. Medical societies in
many countries including the ACC, ASCO and others
have published documents to help providers with
health care policies and guidelines [48–52]. This survey suggests physicians’ support and demand such active involvement from professional societies.
Study limitations

The responses reflect primarily those of physicians.
Many of the addressed issues, including PPE or support
for patient care may not reflect those of other healthcare
workers.
This survey had a good response from a large number of cardiologists and oncologists from different locations involving both academic and nonacademic
doctors. However, there was a strong US response
compared to other countries, likely reflecting the larger number of US members in our collaborative
cardio-oncology network. Response rates are not
available given the multiple sites and organizations
that provided this survey utilizing different local platforms, and therefore, a denominator for response rate
cannot be established. The survey may have sampling
bias and therefore reflect the opinion of physicians
more actively involved with medical professional societies. Therefore, the responses cannot be interpreted
as representative of all cardiologists, oncologists, nor
all institutions at the surveyed locations. Furthermore,
since survey questions were not previously validated,
respondents’ interpretations may vary, and represent
their knowledge and beliefs rather than their institutions’ policies. Moreover, the dynamic nature of this
pandemic may have resulted in different responses if
this survey was taken at a later time.
However, it highlights the similarities in challenges experienced by physicians working in different environments and points to the need for further awareness,
advocacy and collaboration for health care crisis
management.
Advocacy

The health care community remains at the front line
of any public health emergency. Professional societies
have the mandate and duty to work with their governments to derive data-driven policies aimed at protecting the populations they serve. In order to be
better equipped for ongoing and future health care
crises, our survey data imply an expectation that our
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professional societies develop and promote initiatives
in the following areas:
1. Promote the use of new technologies and advocate
for permanent insurance coverage of telemedicine,
particularly for vulnerable at-risk patients. Additional research is needed to identify any disparities
that may be widened by telemedicine.
2. Have mechanisms in place to expand worldwide
production and supply chain of critically needed
medical supplies and equipment (such as PPE,
ventilators) in a very short period of time.
3. Consolidate algorithms to balance all healthcare
needs including pathways for cardiovascular and
cancer care during the pandemic with the goal of
minimizing delay of essential care.
4. Advocate for close collaboration between medical
professional societies and their governments to
develop health care policy that will streamline
population care during health care crisis.
5. Develop, update, and mandate emergency
preparedness in the health care sector to be able to
respond in a coordinated manner to a world-wide
health crisis in a short period of time.

Conclusions
This international collaborative survey provides new
insight onto the impact of the COVID-19 pandemic
on cardiologists and oncologists practices, the lack of
resources encountered in many instances, the geographic regional differences and common issues, and
the almost unanimous claim by physicians for coordinated central health care policies. Understanding
shortcomings and lack of resources experienced during this pandemic and involvement of professional societies in healthcare policy decision making may
provide a blueprint for coordination and preparedness
for future global healthcare crises.
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